Tweehuysen L, et al. - A multicenter prospective cohort study was done to assess drug survival, efficacy, pharmacokinetics, immunogenicity and safety after transitioning treatment from originator infliximab (Remicade®, REM) to biosimilar infliximab (CT-P13) in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis in daily practice. In this cohort, a quarter of patients discontinued CT-P13 amid a half year follow-up, mainly because of an increase in subjective tender joint count and patients' global disease activity and/or subjective AEs, possibly clarified by nocebo and/or incorrect causal attribution impacts.